Licensing, Compliance, and Legal Risks in Entering the Turkish Pharmaceutical Market

In Türkiye, placing a medicinal product for human use on the market requires not only the completion of a technical and scientific development process, but also a multi-layered licensing and regulatory compliance process. The licensing process is carried out by the Turkish Medicines and Medical Devices Agency and involves the assessment of the application, preliminary review, substantive review, possible requests for additional information, post-licensing pharmacovigilance, variations, and market availability obligations.

For manufacturers, importers, marketing authorization holders, and international companies planning to enter the pharmaceutical sector in Türkiye, the licensing process is not merely an authorization procedure. It creates a broad field of compliance, ranging from product classification and the scope of the application dossier to manufacturing site and supply chain documentation, as well as product safety obligations. For this reason, pharmaceutical licensing should be considered not only as a regulatory filing process, but also as a strategic legal risk and compliance matter for companies.

Licensing Authority and the Main Legal Framework in Türkiye

The licensing of medicinal products for human use in Türkiye is carried out by the Turkish Medicines and Medical Devices Agency. Within the current framework, the licensing process is based on legislation that requires the assessment of medicinal products in terms of quality, safety, and efficacy. This structure ensures that pharmaceutical products are subject not only to review at the market entry stage, but also to administrative and technical supervision after the license is granted.

For this reason, the licensing process should not be seen as a limited procedure focused only on the application stage. From a company perspective, licensing is a compliance process that begins before the application and continues through the post-licensing period.

How Does the Licensing Process Begin?

The licensing process begins when the applicant submits the required information and documentation to the Agency. The application dossier includes comprehensive documentation relating to the applicant, the product, the manufacturing site, quality data, and clinical and non-clinical information. The completeness and systematic preparation of the application is essential for the healthy progress of the subsequent review stages.

In practice, this stage is sometimes perceived merely as the submission of technical documents. However, incomplete or disorganized applications may result in delays, additional information requests, or negative outcomes. For this reason, pre-application preparation is one of the most critical phases of the licensing process.

Preliminary Review and Substantive Assessment

Once the application is accepted by the Agency, the preliminary review and substantive assessment stages begin. At this stage, the compliance of the submitted information and documents with the legislation, the product’s quality structure, safety profile, and efficacy under the proposed conditions of use are evaluated.

An important point for companies is that the time periods set out in the legislation do not necessarily operate in the same way for every file. Additional information and document requests, technical reviews, analytical procedures, and the nature of the application itself may directly affect the duration of the licensing process. Therefore, process planning should take into account not only theoretical deadlines, but also possible delays in practice.

Which Criteria Are Taken into Account When Granting a License?

Three core criteria stand out in the assessment of a medicinal product for human use: quality, safety, and efficacy. The product is expected to demonstrate appropriate pharmaceutical characteristics, proven efficacy under the intended conditions of use, and an acceptable safety profile.

Accordingly, licensing is not merely an administrative approval process. The application dossier must present scientific, technical, and legal consistency as a whole. Companies should therefore not only focus on submitting the application, but also on ensuring that the dossier is defensible and sustainable.

Post-Licensing Obligations

The granting of a license does not mean that the company’s obligations come to an end. The marketing authorization holder remains responsible for fulfilling certain obligations throughout the time the product is on the market. In this context, pharmacovigilance activities, safety-related reporting, quality updates, and required administrative filings are of particular importance.

One of the areas most frequently overlooked by companies in the post-licensing period is the proper management of product-related changes. Changes in manufacturing sites, updates to product information, technical variations, and certain quality-related processes may all require separate evaluation. For this reason, post-licensing obligations should be handled with at least as much care as the initial application.

Why Are Variation and Update Procedures Important?

Once a product has been licensed, all product-related changes must be evaluated in accordance with the applicable legislation. In practice, one of the most important issues for companies is correctly determining which procedure applies to which type of change. Otherwise, even a change that may appear minor from a technical or administrative perspective may create compliance issues in terms of the license.

For this reason, issues such as manufacturing processes, quality structure, product information, packaging elements, or changes relating to the marketing authorization holder each require separate attention. Timely and properly structured management of post-licensing updates directly affects a company’s regulatory compliance.

Market Release and Market Availability Obligations

In the pharmaceutical sector, legal and administrative responsibility does not end with the granting of the license. Market release, additional authorization and review requirements for certain product groups, market availability obligations, and responsibilities relating to the protection of public health are also important.

From a company perspective, this area may appear to be merely the technical continuation of the licensing process, but in reality it is where commercial planning and legal compliance intersect. Problems that may arise in relation to market supply, continuity of availability, and product safety can lead not only to commercial consequences, but also to administrative ones.

Main Legal Risks for Companies

Legal risks in entering the Turkish pharmaceutical market are not limited to whether a license can be obtained. In practice, the main risk areas include:

• Incorrect product classification at the outset
• Incomplete or non-compliant preparation of the application dossier
• Deficiencies in the manufacturing chain and quality documentation
• Failure to respond to additional information requests in a timely manner
• Neglect of post-licensing variation and update procedures
• Insufficient management of pharmacovigilance obligations
• Overlooking market release and availability obligations
• Failure to establish a clear legal structure for the distributor, local representative, or marketing authorization holder

For this reason, pharmaceutical licensing is not merely a matter for regulatory teams. It is a multi-dimensional field of compliance that should be evaluated jointly by legal, quality, supply chain, pharmacovigilance, and commercial teams.

What Is the Right Approach for Entering the Turkish Pharmaceutical Market?

For companies planning to enter the Turkish market, the most appropriate approach is to treat licensing not as a one-time administrative approval, but as an ongoing compliance process extending from the pre-application stage through the post-licensing period. Within this process, the company structure, product strategy, local representation model, and technical dossier should all support one another.

Particularly for international companies, compliance with local legislation, preparation of the product dossier in line with current requirements, and the proper structuring of post-licensing obligations are of great importance. A successful market entry strategy depends not only on filing the application, but on managing the process in a controlled and predictable manner from beginning to end.

Frequently Asked Questions

Is pharmaceutical licensing only a technical application process?

No. Although the licensing process involves technical and scientific assessment, it also gives rise to legal and administrative obligations.

Does the company’s responsibility end once the license is granted?

No. Post-licensing obligations such as pharmacovigilance, variations, quality updates, and market availability continue after the license is granted.

What are the most critical risk areas for international pharmaceutical companies?

The preparation of the application dossier in compliance with local legislation, the correct structuring of the local representative and marketing authorization holder model, and the effective management of post-licensing compliance obligations are among the most important areas.

Does the post-licensing process work in the same way for every product?

No. Depending on the nature of the product, additional authorizations, specific evaluations, or special follow-up procedures may apply.

Conclusion

In Türkiye, pharmaceutical licensing is not limited to the submission of a technical dossier to the competent authority. It is a comprehensive field of regulation and compliance that must be evaluated together with application preparation, review, possible additional requests, post-licensing obligations, variation management, and market release responsibilities.

For this reason, the most sound approach for companies planning to enter the Turkish pharmaceutical market is to treat the licensing process as part of a long-term legal and administrative compliance strategy beginning before the application stage.

To receive professional assistance, you can contact us via our contact page.